Compare Medpace Holdings Inc (MEDP) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs OneSpan Inc — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while OneSpan Inc trades at $16.57 (market cap $600.69M). The key difference: Medpace Holdings Inc is far larger — about 28.1× OneSpan Inc's market cap, and OneSpan Inc pays a 3.19% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | OSPN | |
|---|---|---|
Market Cap | $16.90B | $600.69M |
Sector | Technology | Technology |
52-Week High | $620.59 | $16.78 |
52-Week Low | $393.42 | $10.15 |
Enterprise Value | $16.52B | $569.77M |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
OneSpan (OSPN) trades at $16.53, up 0.98% in the last session, with a bullish technical signal from moving averages. The stock shows strong profitability with a net income margin of 27.76% and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and the launch of DigipassONE, supporting growth in subscription revenue.
Outlook remains positive with a consensus price target of $17.00, though risks include declining net cash flow and competitive pressures. The stock offers value with a P/E of 9.21, but investors should monitor execution on guidance and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
